BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36402451)

  • 1. Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS.
    Choi SJ; Choi SH; Kim DW; Kwag M; Byun JH; Won HJ; Shin YM
    J Hepatol; 2023 Mar; 78(3):596-603. PubMed ID: 36402451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LI-RADS version 2018 for hepatocellular carcinoma < 1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging.
    Jang HJ; Choi SH; Choi SJ; Choi WM; Byun JH; Won HJ; Shin YM
    Eur Radiol; 2023 Aug; 33(8):5792-5800. PubMed ID: 37017700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LI-RADS threshold growth based on tumor growth rate can improve the diagnosis of hepatocellular carcinoma ≤ 3.0 cm.
    Jeong B; Choi SJ; Choi SH; Jang HJ; Byun JH; Won HJ; Shin YM
    Eur Radiol; 2024 Feb; 34(2):1210-1218. PubMed ID: 37589898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
    Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
    J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should Threshold Growth Be Considered a Major Feature in the Diagnosis of Hepatocellular Carcinoma Using LI-RADS?
    Park JH; Chung YE; Seo N; Choi JY; Park MS; Kim MJ
    Korean J Radiol; 2021 Oct; 22(10):1628-1639. PubMed ID: 34269533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity.
    Jiang H; Song B; Qin Y; Wei Y; Konanur M; Wu Y; Zaki IH; McInnes MDF; Lafata KJ; Bashir MR
    J Magn Reson Imaging; 2022 Feb; 55(2):493-506. PubMed ID: 34236120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Threshold growth has a limited role in differentiating hepatocellular carcinoma from other focal hepatic lesions.
    Lyu R; Wang D; Hu W; Gao Z; Yu C; Wang J; Li M; Jia K
    BMC Med Imaging; 2023 Dec; 23(1):201. PubMed ID: 38049717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
    Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
    AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
    [No Abstract]   [Full Text] [Related]  

  • 10. Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.
    Chen J; Kuang S; Zhang Y; Tang W; Xie S; Zhang L; Rong D; He B; Deng Y; Xiao Y; Shi W; Fowler K; Wang J; Sirlin CB
    Abdom Radiol (NY); 2021 Apr; 46(4):1530-1542. PubMed ID: 33040166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
    Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
    AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
    [No Abstract]   [Full Text] [Related]  

  • 12. Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis.
    Goins SM; Jiang H; van der Pol CB; Salameh JP; Lam E; Adamo RG; McInnes MDF; Costa AF; Tang A; Alhasan AS; Allen BC; Reiner CS; Clarke C; Cerny M; Wang J; Choi SH; Fraum TJ; Ludwig DR; Song B; Joo I; Kang Z; Kierans AS; Kim SY; Kwon H; Ronot M; Podgórska J; Rosiak G; Song JS; Bashir MR
    Radiology; 2023 Dec; 309(3):e231656. PubMed ID: 38112549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
    Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.
    Ludwig DR; Fraum TJ; Cannella R; Ballard DH; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
    Abdom Radiol (NY); 2019 Jun; 44(6):2116-2132. PubMed ID: 30798397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suboptimal performance of LI-RADS v2018 on gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in liver transplant candidates.
    Oh NE; Choi SH; Kim S; Lee H; Jang HJ; Byun JH; Won HJ; Shin YM
    Eur Radiol; 2024 Jan; 34(1):465-474. PubMed ID: 37532900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Performance of LI-RADS v2018 versus KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging with Hepatobiliary Agent: A Systematic Review and Meta-Analysis of Comparative Studies.
    Shin J; Lee S; Yoon JK; Son WJ; Roh YH; Chung YE; Choi JY; Park MS
    Gut Liver; 2023 May; 17(3):466-474. PubMed ID: 36317516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study.
    Jiang H; Song B; Qin Y; Konanur M; Wu Y; McInnes MDF; Lafata KJ; Bashir MR
    J Magn Reson Imaging; 2022 Aug; 56(2):399-412. PubMed ID: 34994029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria.
    Zhang Y; Tang W; Xie S; Chen J; Zhang L; Rong D; Kuang S; He B; Wang J
    Eur Radiol; 2021 Oct; 31(10):7715-7724. PubMed ID: 33782766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver Imaging Reporting and Data System version 2018 category 5 for diagnosing hepatocellular carcinoma: an updated meta-analysis.
    Lee S; Kim YY; Shin J; Roh YH; Choi JY; Chernyak V; Sirlin CB
    Eur Radiol; 2024 Mar; 34(3):1502-1514. PubMed ID: 37656177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simplified LI-RADS for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI.
    Kwag M; Choi SH; Choi SJ; Byun JH; Won HJ; Shin YM
    Radiology; 2022 Dec; 305(3):614-622. PubMed ID: 35972362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.